Ashley JD - Reneo Pharmaceuticals Chief Officer

RPHMDelisted Stock  USD 18.20  1.40  8.33%   

Insider

Ashley JD is Chief Officer of Reneo Pharmaceuticals
Age 52
Phone858 283 0280
Webhttps://reneopharma.com

Reneo Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.3372) % which means that it has lost $0.3372 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.54) %, meaning that it created substantial loss on money invested by shareholders. Reneo Pharmaceuticals' management efficiency ratios could be used to measure how well Reneo Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
Reneo Pharmaceuticals currently holds 973 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Reneo Pharmaceuticals has a current ratio of 15.52, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Reneo Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Kristina ZambourasC4 Therapeutics
N/A
Klaus FruehVir Biotechnology
64
Ellen MBAWerewolf Therapeutics
48
Reshma ShettyGinkgo Bioworks Holdings
43
CPA CTPCns Pharmaceuticals
44
Stephanie YaoKronos Bio
N/A
Vicky HahneCelcuity LLC
58
Eric LindquistCelcuity LLC
N/A
Reid LeonardWerewolf Therapeutics
65
Behrad DerakhshanEdgewise Therapeutics
44
Divya ChariSummit Therapeutics PLC
56
Alan RussellEdgewise Therapeutics
54
Kyle PiskelAdaptive Biotechnologies Corp
40
Dabt PhCelcuity LLC
67
Campbell HairSummit Therapeutics PLC
N/A
Tycho PetersonAdaptive Biotechnologies Corp
50
Keith MDPrime Medicine, Common
70
Jason KellyGinkgo Bioworks Holdings
43
Lauren WhiteC4 Therapeutics
N/A
Austin CheGinkgo Bioworks Holdings
N/A
Launa AspesletHepion Pharmaceuticals
N/A
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company was incorporated in 2014 and is headquartered in Irvine, California. Reneo Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 29 people. Reneo Pharmaceuticals (RPHM) is traded on NASDAQ Exchange in USA and employs 8 people.

Management Performance

Reneo Pharmaceuticals Leadership Team

Elected by the shareholders, the Reneo Pharmaceuticals' board of directors comprises two types of representatives: Reneo Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Reneo. The board's role is to monitor Reneo Pharmaceuticals' management team and ensure that shareholders' interests are well served. Reneo Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Reneo Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Gregory Flesher, CEO President
Alejandro MD, Chief Officer
Ashley JD, Chief Officer
Wendy MBA, Consultant
Vineet Jindal, Consultant
Michael Cruse, Chief Officer
Jennifer Lam, Principal Officer
Lynn Purkins, Senior Development
Michael Grey, Founder Chairman

Reneo Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Reneo Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Other Consideration for investing in Reneo Stock

If you are still planning to invest in Reneo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reneo Pharmaceuticals' history and understand the potential risks before investing.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Stocks Directory
Find actively traded stocks across global markets
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
CEOs Directory
Screen CEOs from public companies around the world
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account